YAS | ياس CLINIC | كلينك

INVITATION

Hematopoietic Stem Cell Transplantation for Multiple Sclerosis Tuesday, September 21st, 2021, 8:00 PM Webinar

Yas Clinic Group, along with ADSCC invites you to attend the first instalment of the Yas Clinic Speaker Series: Exploring the Frontiers of Medicine.

The series will feature lectures by world renowned physicians and scientists, providing expert insight into a range of innovative topics relevant to healthcare issues in the region.

We are proud to welcome **Richard K. Burt, MD**, founding member, Acting CEO, Genani Biotech Corporation.

Dr Burt is a Professor of Medicine at Northwestern University Feinberg School of Medicine and a Fulbright Scholar. He endeavored for 35 years, first with animal models then with some of the world's first clinical trials, to bring the field of stem cell and cellular therapy to the patient's bedside.



Guest Speaker Richard K. Burt, MD

Dr Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple clerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronicinflammatory demyelinating polyneuropathy (CIDP) and published the world's first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis.

In this presentation Dr Burt will discuss the following:

Outcome of HSCT for relapsing remitting multiple sclerosis (RRMS) is dependent on two variables:

- 1- Patient selection
- 2- Conditioning regimen

Patient selection

- Active RRMS, hematopoietic stem cell transplantation (HSCT) halts disease progression, improves neurologic disability and quality of life, provides a drug-free prolonged remission, and is cost effective compared to DMTs.
- Secondary progressive MS (SPMS) without recent disease activity on MRI (non-active, naSPMS) is NOT an indication for HSCT.
- SPMS with recent activity on the MRI (active SPMS, aSPMS) should only be considered for HSCT in a randomized controlled trial against a DMT control arm.

Conditioning regimen

• The safest nonmyeloabaltive conditioning regimen should be utilized

To register for this lecture, please click here.